Hepatic fibrosis inhibitor

Details Hepatic fibrosis inhibitor Hepatic fibrosis inhibitor

2009-12-07

2010-12-07

Witherspoon, Sikarl A (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Oxygen containing

C514S724000, C514S730000

Reexamination Certificate

active

07847132

ABSTRACT:
The progression of hepatic fibrosis and hepatic cirrhosis caused by various hepatic disorders and damages such as chronic hepatitis can be restrained by hepatic fibrosis inhibitor containing a compound represented by the following chemical formula:wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6, or alkoxycarbonyl group with a carbon number of 2 to 6.

REFERENCES:
patent: 5-301836 (1993-11-01), None
patent: 6-100441 (1994-04-01), None
patent: 8-67627 (1996-03-01), None
patent: 2002-241366 (2002-08-01), None
patent: 2004-352661 (2004-12-01), None
patent: 2005-41837 (2005-02-01), None
patent: 2005-343889 (2005-12-01), None
patent: 2007-186519 (2007-07-01), None
patent: 00/31135 (2000-06-01), None
Jian Wu et al., “Hepatic stellate cells: a target for the treatment of liver fibrosis”, Journal of Gastroenterology, vol. 35, No. 9, pp. 665-672, 2000.
Tadayuki Hino et al., “HTHQ (1-0-hexyl-2,3,5-trimethylhydroquinone), an anti-lipid-peroxidative compound: its chemical and biochemical characterizations”, Biochimica et. Biophysica Acta, 1425, pp. 47-60, Sep. 16, 1998.
Communication dated Feb. 24, 2010 issued in connection with the European application corresponding to the present U.S. application.
European Search Report dated Sep. 4, 2009 issued in corresponding European Application No. 09 15 7413.
Giuseppe Poli, “Pathogenesis of liver fibrosis: role of oxidative stress”, Molecular Aspects of Medicine, 21, pp. 49-98, XP-002540587, 2000.
Kuniharu et al., Akita, “Inhibiting Hepatic Fibrosis Against Cirrhosis”, Jpn J Med Pharma Sci (Igaku to Yakugaku), Japan, May 2001, vol. 45-5, pp. 720-728.
Fujii et al., Hideki, “Molecular Mechanism of Hepatic Fibrosis—Mainly Stellate Cell”, Weekly Journal of Clinical and Experimental Medicine (Igaky no Ayumi), Japan, 2006, pp. 198-202.

Affiliated with

Also associated with

Rating

Hepatic fibrosis inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hepatic fibrosis inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatic fibrosis inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4226532